Sou Hu Cai Jing·2025-10-31 00:21Core Insights - Spring Medical (688236.SH) reported a total revenue of 756 million yuan for Q3 2025, with a net profit attributable to shareholders of 192 million yuan and a net cash inflow from operating activities of 175 million yuan [1]. Financial Performance - The company's latest debt-to-asset ratio stands at 15.65% [3]. - The gross profit margin is 67.27%, which is a decrease of 2.03 percentage points compared to the same period last year [3]. - The return on equity (ROE) is reported at 6.42% [3]. - The diluted earnings per share (EPS) is 0.50 yuan [3]. - The total asset turnover ratio is 0.22 times, ranking 79th among disclosed peers [3]. - The inventory turnover ratio is 0.44 times, ranking 127th among disclosed peers [3]. Shareholder Structure - The number of shareholders is 6,164, with the top ten shareholders holding a total of 249 million shares, accounting for 64.88% of the total share capital [3]. - The top ten shareholders and their respective holdings are as follows: - Shi Chunbao: 31.3 million shares - Yue Mujun: 24.8 million shares - Beijing Panmao Investment Management Co., Ltd.: 4.50 million shares - Hong Kong Central Clearing Limited: 0.77 million shares - Huaxia Bank Co., Ltd.: 0.74 million shares - Huang Dong: 0.66 million shares - Beijing Panmao Investment Management Co., Ltd.: 0.65 million shares - Agricultural Bank of China: 0.55 million shares - Huatai Securities Asset Management: 0.43 million shares - Beijing Chunli Zhengda Medical Device Co., Ltd.: 0.36 million shares [3].